Last updated: August 2, 2026
PRIMAXIN is the original branded formulation of imipenem and cilastatin, an injectable carbapenem antibiotic developed and commercialized by Merck. Its commercial trajectory has moved from premium hospital antibiotic to mature generic product. Core patent protection and branded exclusivity have expired, generic competition is established, and Merck no longer reports PRIMAXIN as a material standalone revenue product. Current market value is concentrated in generic hospital supply, contract manufacturing, procurement access, and differentiated successor products such as RECARBRIO.
What is PRIMAXIN and how does the drug work?
PRIMAXIN is an intravenous or intramuscular antibacterial combination containing imipenem, a carbapenem antibiotic, and cilastatin, a renal dehydropeptidase-I inhibitor.
| Attribute |
PRIMAXIN |
| Active ingredients |
Imipenem and cilastatin |
| Drug class |
Carbapenem antibacterial |
| Original developer |
Merck & Co. |
| Initial FDA approval |
1985 |
| Primary route |
Intravenous; intramuscular presentations also existed |
| Main setting |
Hospital and institutional care |
| Primary use |
Serious susceptible bacterial infections |
| Current commercial position |
Mature product with generic competition |
| Key successor product |
RECARBRIO, imipenem/cilastatin/relebactam |
Imipenem inhibits bacterial cell-wall synthesis. Cilastatin blocks renal metabolism of imipenem and increases systemic exposure. PRIMAXIN has historically been used for severe intra-abdominal, lower respiratory, urinary tract, gynecologic, septicemic, bone and joint, and skin and soft-tissue infections, subject to susceptibility and labeling restrictions.[1]
The product is administered in hospitals because of its parenteral route, clinical severity profile, renal dosing requirements, and antimicrobial stewardship controls. Those characteristics limit retail pharmacy exposure but support institutional purchasing and formulary-driven demand.
When did PRIMAXIN lose exclusivity?
PRIMAXIN’s market exclusivity ended decades ago. Its original composition and product patents expired after the product’s 1985 launch, and generic imipenem-cilastatin products entered the U.S. market after the relevant patent barriers ceased to protect the product.
The commercial timeline is broadly as follows:
| Period |
Commercial development |
| 1985 |
FDA approval of PRIMAXIN IV |
| Late 1980s to 1990s |
Expansion in hospital anti-infective use |
| 1990s to early 2000s |
Additional formulations, labeling changes and manufacturing-related protections |
| Mid-2000s onward |
Generic imipenem-cilastatin competition becomes established |
| 2010s |
Brand value declines; hospital purchasing shifts toward generic supply |
| 2019 |
FDA approval of Merck’s RECARBRIO |
| 2020s |
PRIMAXIN remains a mature, low-growth or declining branded asset |
The original commercial opportunity was protected by product, formulation, manufacturing and regulatory exclusivities associated with a first-in-class carbapenem. Those protections no longer provide meaningful exclusivity for ordinary imipenem-cilastatin products.
What patents protect PRIMAXIN?
The principal PRIMAXIN patent estate historically covered the imipenem compound, cilastatin combination, pharmaceutical compositions, stabilization approaches, dosage forms and manufacturing processes. Most commercially relevant U.S. protection has expired.
No active core patent should be assumed to prevent the manufacture or sale of ordinary generic imipenem-cilastatin. Remaining patent activity, where present, would be more likely to concern specific formulations, manufacturing processes, packaging, delivery systems or improved combinations rather than the basic PRIMAXIN combination.
What formulation patents cover imipenem-cilastatin?
Imipenem is chemically unstable and requires formulation controls. Commercial protection historically focused on:
- Stable injectable compositions.
- Combination ratios between imipenem and cilastatin.
- pH control and buffering systems.
- Dry powders for reconstitution.
- Manufacturing and lyophilization processes.
- Container-closure and storage configurations.
- Intramuscular formulations using different diluents.
These protections mattered during the branded period because injectable beta-lactam products require validated stability, sterility and container systems. They have less strategic value today because generic manufacturers have developed approved manufacturing routes and hospital buyers commonly prioritize supply continuity and price.
Are method-of-use patents still relevant?
Method-of-use protection for the original labeled infections has expired or is commercially immaterial. PRIMAXIN’s label covers broad serious bacterial infections, making disease-specific patent differentiation less important than for oncology or specialty medicines.
Later innovation in the imipenem franchise shifted toward resistance management. RECARBRIO combines imipenem and cilastatin with relebactam, a beta-lactamase inhibitor. That product targets certain resistant Gram-negative infections and has a separate regulatory and patent position from PRIMAXIN.[2]
What is the FDA regulatory status of PRIMAXIN?
PRIMAXIN was approved by the FDA as a prescription antibacterial product. Generic versions of imipenem and cilastatin have been approved through abbreviated new drug applications, provided they demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable injectable-product requirements.
The FDA regulatory position has several commercial implications:
- PRIMAXIN is an established active ingredient combination with extensive clinical history.
- Generic entry does not require replication of the original clinical development program.
- Hospital buyers can substitute approved generic products subject to procurement, supply and formulary requirements.
- The product remains exposed to manufacturing disruptions because sterile injectable production is technically demanding.
- Regulatory value now resides primarily in approved manufacturing capacity and reliable supply rather than brand differentiation.
The branded PRIMAXIN franchise should be distinguished from RECARBRIO. RECARBRIO is a newer fixed-dose combination containing imipenem, cilastatin and relebactam. It was approved for selected adult infections caused by susceptible Gram-negative organisms, including infections involving resistant pathogens.[2]
What is the Orange Book status of PRIMAXIN?
The Orange Book is most relevant to active, marketed drug products and their listed patents. PRIMAXIN’s historical Orange Book entries supported patent certification and generic approval analysis during the period when relevant patents remained in force.
The current commercial question is not whether a generic must overcome a live core PRIMAXIN patent. It is whether a manufacturer can obtain and maintain approval for an imipenem-cilastatin injectable product while satisfying sterile manufacturing, quality, stability, labeling and supply obligations.
For market analysis, the operative conclusion is:
| Orange Book issue |
PRIMAXIN implication |
| Core composition patent |
Expired |
| Original branded exclusivity |
Expired |
| Generic approval pathway |
Established |
| Paragraph IV exposure |
Primarily historical |
| Current market barrier |
Manufacturing and supply execution |
| Brand-based price premium |
Limited |
Which companies are challenging PRIMAXIN?
PRIMAXIN has been challenged by generic manufacturers rather than by a current high-profile Paragraph IV litigation campaign. Generic competition has come from companies operating in sterile injectable antibiotics, including large generic manufacturers and hospital-product suppliers.
The market is fragmented by country. U.S. suppliers can include manufacturers or marketing affiliates associated with companies such as Sandoz, Hikma, Fresenius Kabi, Pfizer, Eugia, Dr. Reddy’s and other approved generic suppliers, depending on product availability and the relevant period.
Supplier presence changes over time because injectable antibiotics are vulnerable to:
- Manufacturing observations or warning letters.
- Drug shortages.
- Raw-material constraints.
- Batch failures.
- Contract manufacturing changes.
- Hospital tender losses.
- Product discontinuations.
No current branded PRIMAXIN litigation appears to define the market in the manner of an active pharmaceutical patent dispute. The key competitive contest is supply reliability and institutional contracting.
How strong is the PRIMAXIN patent estate?
The historical patent estate was strong enough to support a major branded hospital franchise but is weak as a current barrier to generic entry.
| Patent-estate dimension |
Current assessment |
| Core molecule |
No meaningful remaining exclusivity |
| Imipenem-cilastatin combination |
Mature and genericized |
| Broad infection indications |
Expired or commercially weak |
| Injectable formulation |
Potential technical know-how value, not a broad market barrier |
| Manufacturing processes |
May retain trade-secret value, but limited blocking power |
| Recarbrio combination |
Separate and more relevant newer estate |
| Biosimilar protection |
Not applicable |
The most defensible residual advantage is operational rather than legal. Merck’s historical process knowledge, regulatory files, quality systems and manufacturing experience could support supply, but these assets do not prevent approved competitors from entering.
How many patents cover PRIMAXIN today?
A precise count of currently enforceable patents requires a live review of the FDA Orange Book, USPTO records, international patent registers and product-specific ownership data. The commercially relevant conclusion is that no active core PRIMAXIN patent estate materially blocks generic imipenem-cilastatin competition in the United States.
Historical patent counts can be misleading because they may include expired patents, continuations, foreign counterparts, manufacturing claims and patents that never created a practical market barrier.
What generic entry risks exist for PRIMAXIN?
Generic entry risk is high because the product has no meaningful brand exclusivity and the active ingredient combination is well established. The principal risk to generic suppliers is not patent litigation. It is execution in sterile injectable manufacturing.
What limits generic supply?
Generic imipenem-cilastatin suppliers face several barriers:
- Complex sterile manufacturing.
- Validation of aseptic processing.
- Stability and reconstitution requirements.
- Specialized packaging.
- Hospital quality audits.
- Active pharmaceutical ingredient sourcing.
- Limited tolerance for contamination or batch failure.
- Contracting pressure from group purchasing organizations.
These barriers can reduce the number of active suppliers even when patent protection is absent. They can also create temporary pricing power during shortages. That pricing power is usually unstable because hospitals and public purchasers seek alternative suppliers once availability improves.
How does PRIMAXIN compare with RECARBRIO?
RECARBRIO is the main Merck product relevant to the modern imipenem franchise. It adds relebactam to imipenem and cilastatin and targets certain infections involving resistant Gram-negative bacteria.
| Factor |
PRIMAXIN |
RECARBRIO |
| Composition |
Imipenem/cilastatin |
Imipenem/cilastatin/relebactam |
| Product generation |
Original carbapenem combination |
Newer resistance-focused combination |
| Core patent status |
Expired |
Later patent estate |
| Competitive market |
Generic injectable competition |
Branded specialty hospital product |
| Clinical differentiation |
Broad established use |
Selected resistant infections |
| Price position |
Low-cost generic or mature brand |
Premium branded hospital therapy |
| Commercial strategy |
Volume and supply |
Resistance management and targeted use |
| Main risk |
Price erosion and supply competition |
Restricted use, stewardship and payer control |
RECARBRIO does not restore exclusivity to PRIMAXIN. It creates a separate commercial product with a distinct intellectual-property and clinical positioning strategy.
What is the financial trajectory of PRIMAXIN?
PRIMAXIN’s financial trajectory is consistent with a mature hospital anti-infective:
- Initial growth followed adoption of carbapenems in serious hospital infections.
- Revenue expanded with broader hospital use and international commercialization.
- The brand faced gradual erosion after patent expiry and generic entry.
- Price and volume shifted toward institutional procurement.
- Merck’s standalone PRIMAXIN revenue became immaterial or was absorbed into broader product reporting.
- Strategic value shifted from the legacy brand to newer anti-infective products, including RECARBRIO.
Merck does not generally disclose PRIMAXIN revenue as a separate current reporting line. Public financial statements aggregate products into broader pharmaceutical categories, making a precise current PRIMAXIN revenue series unavailable from company filings.[3]
What drives PRIMAXIN revenue?
Current revenue depends on:
- Hospital admissions involving susceptible serious infections.
- Carbapenem utilization.
- Generic and branded supplier mix.
- Public and private hospital tenders.
- Shortages of competing beta-lactams.
- Antimicrobial stewardship policies.
- Regional resistance patterns.
- Supply continuity.
- Contract pricing.
The product has limited exposure to retail prescription growth. Its market is institutional and procurement-led.
What is the revenue exposure for Merck?
PRIMAXIN is unlikely to represent a material contributor to Merck’s present consolidated revenue. Merck’s major pharmaceutical growth drivers have shifted toward oncology, vaccines, immunology and newer specialty medicines. Legacy antibiotics such as PRIMAXIN have limited strategic importance relative to those franchises.
The financial value of the imipenem platform is more relevant through differentiated successor products and anti-infective portfolio strategy than through the original PRIMAXIN brand.
What patent litigation and settlement agreements affect PRIMAXIN?
No active, market-defining patent litigation or settlement agreement is central to ordinary U.S. imipenem-cilastatin competition. Historical generic entry would have been assessed through abbreviated new drug application certifications, including Paragraph III or Paragraph IV certifications depending on the patent record at the time.
The present litigation risk is more likely to arise from:
- Product liability.
- Manufacturing quality.
- Supply contracts.
- False advertising or promotional claims.
- Procurement disputes.
- Patent disputes involving newer combinations such as RECARBRIO.
PRIMAXIN’s expired core patents do not create a credible basis for delaying ordinary generic entry today.
What is the competitive landscape for imipenem-cilastatin?
The competitive landscape has three tiers:
Generic imipenem-cilastatin
This segment competes on price, availability, quality history, vial configuration, dosage strengths, delivery systems and contracting access. Products are generally sold through hospitals, distributors, government procurement channels and group purchasing organizations.
Alternative carbapenems
Meropenem and doripenem compete in overlapping hospital indications. Ertapenem competes in selected infections but has a different spectrum and dosing profile. Choice depends on pathogen, resistance mechanism, renal function, dosing convenience, formulary policy and stewardship rules.
Newer resistance-focused agents
Products such as RECARBRIO and other beta-lactam/beta-lactamase inhibitor combinations compete for cases involving resistant organisms. They are less direct substitutes for routine generic PRIMAXIN use but can capture premium treatment segments.
What are the generic launch scenarios for PRIMAXIN?
The most likely commercial scenarios are:
| Scenario |
Market outcome |
| Stable supply |
Continued low-price generic competition and limited brand relevance |
| Supplier withdrawal |
Temporary shortage-driven price increases |
| Hospital tender consolidation |
Lower supplier count and stronger volume discounts |
| Increased carbapenem resistance |
Shift toward newer targeted agents |
| Manufacturing disruption |
Short-term scarcity and substitution into meropenem or other agents |
| New clinical restrictions |
Lower routine use but sustained demand in severe infections |
Geographically, mature generic competition is expected in the United States, Europe and other regulated markets. Lower-income markets may have more variable supplier quality, procurement pricing and availability. Local registration, government tenders and domestic manufacturing policy can materially affect market access.
What manufacturing and intellectual-property barriers remain?
The principal barriers are technical and regulatory rather than patent-based. Imipenem-cilastatin requires reliable sterile production, validated storage and reconstitution performance, and consistent active pharmaceutical ingredient supply.
Trade secrets may protect process parameters, impurity controls, yield optimization and stability methods. Those protections can improve economics but generally do not block a competitor that develops and validates an independent process.
The strongest commercial moat is therefore a combination of:
- FDA-approved sterile capacity.
- Reliable API sourcing.
- A strong inspection and compliance record.
- Hospital contracts.
- Distribution reach.
- Ability to maintain supply during shortages.
Key Takeaways
- PRIMAXIN is the original Merck imipenem-cilastatin injectable antibiotic, approved by the FDA in 1985.
- Core patent protection and branded exclusivity have expired.
- Generic competition is established, and current competition is driven by price, supply and hospital contracting.
- PRIMAXIN has no meaningful biosimilar issue because it is a small-molecule antibacterial, not a biologic.
- Formulation and manufacturing know-how remain relevant but do not create a broad blocking patent position.
- Merck does not report current PRIMAXIN revenue as a distinct material financial line.
- RECARBRIO is the commercially relevant newer Merck product built on the imipenem-cilastatin platform.
- Shortages and sterile manufacturing failures can create temporary pricing power for generic suppliers.
- The current value of PRIMAXIN is operational and supply-based, not patent-based.
- The main long-term risk is substitution toward alternative carbapenems and newer resistance-focused agents.
FAQs
Is PRIMAXIN still sold in the United States?
The PRIMAXIN brand has limited commercial relevance in the United States because generic imipenem-cilastatin products dominate the mature market. Availability depends on product status, supplier strategy and hospital procurement.
Is imipenem-cilastatin a generic drug?
Yes. Imipenem-cilastatin is available from generic manufacturers in injectable formulations approved through the FDA abbreviated approval pathway.
Does PRIMAXIN have biosimilars?
No. PRIMAXIN is a small-molecule drug combination. Its competitors are generics, not biosimilars.
Is RECARBRIO a replacement for PRIMAXIN?
RECARBRIO is a separate product, not a direct replacement in every clinical setting. It adds relebactam and is positioned for selected resistant Gram-negative infections.
Can a generic manufacturer launch imipenem-cilastatin without a Paragraph IV challenge?
Yes. A manufacturer can rely on applicable patent certifications, including a certification that no relevant patent blocks approval or a certification addressing expired patents. A Paragraph IV challenge is not required when no unexpired blocking patent remains.
References
-
Merck & Co., Inc. (n.d.). PRIMAXIN IV prescribing information. U.S. Food and Drug Administration labeling archive.
-
U.S. Food and Drug Administration. (2019). FDA approves new treatment for complicated urinary tract and intra-abdominal infections. https://www.fda.gov
-
Merck & Co., Inc. (2024). Annual report for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
-
U.S. Food and Drug Administration. (2024). Drug shortages: Injectable antibiotics and supply information. https://www.fda.gov
